
Please try another search
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Peter Cicala | - | 2024 | Member of the Board |
James A. Bristol | 77 | 2023 | Independent Chairman of the Board |
Christopher Rohde | - | 2021 | Member of Scientific Advisory Board |
Michael Andreeff | - | 2021 | Member of Scientific Advisory Board |
William A. Wexler | 65 | 2022 | Independent Director |
Sol J. Barer | 78 | - | Advisor to the Board |
Blythe Sather | - | 2024 | Member of Scientific Advisory Board |
Jerome Bernard Zeldis | 75 | 2024 | Member of Scientific Advisory Board |
Sanjeev Luther | 62 | 2024 | CEO, President & Director |
Anna Helena Jonsson | - | 2025 | Member of Scientific and Medical Advisory Board |
Amir Anthony Jazaeri | - | 2025 | Member of Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review